Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06684613

Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics

This study addresses the need for HIV prevention to be integrated into counseling visits at sexual and reproductive health clinics.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Yale Clinical and Community Research

New Haven, Connecticut, 06519, United States

Location status: Recruiting

Location contact

Carolina Price, MPA

CONTACT

[email protected]

203-499-8075

Jaimie P Meyer, MD

CONTACT

[email protected]

2037376233

Jaimie P Meyer, MD

PRINCIPAL_INVESTIGATOR

Sangini S Sheth, MD

PRINCIPAL_INVESTIGATOR

About this study

The purpose of this study is to expand and enhance a PrEP decision aid to include the full array of available formulation options and then integrate its delivery into sexual and reproductive health settings during counseling visits, where PrEP can be provided to all women who are interested. Rooted in health implementation frameworks, this study evaluates health and implementation determinants simultaneously along: 1) innovation characteristics; 2) clinical encounter; 3) recipients; and 4) context.

In Aim 1, patients (n=15-20), clinicians (n=10), and staff (n=10) at sexual and reproductive health clinics across Greater New Haven, CT will be engaged for semi-structured interviews to expand and enhance an existing PrEP decision aid to include all available formulations and optimize its integration into sexual and reproductive health clinics. Qualitative interviews will inform infrastructure development to support PrEP delivery in sexual and reproductive health clinics.

In Aim 2 (a hybrid Type 2 effectiveness-implementation study), patients will be randomized (n=50) to receive either the PrEP decision aid or generic PrEP information prior to a clinician visit. In follow-up interviews immediately post-visit, and at Months 3 and 6, primary outcomes are clinical efficacy (PrEP initiation) and implementation (using Proctor definitions for feasibility, acceptability, penetration, and adoption) that are important for future planned scale-up.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Patients (inclusion):

  • Woman
  • Aged 18 years or older
  • Have a uterus
  • Do not have HIV (by self-report)
  • Not currently on PrEP
  • Comfortable conversing in English or Spanish
  • Able to participate in informed consent procedures

Patients (exclusion):

  • People who cannot become pregnant (i.e., have had a hysterectomy or tubal ligation)
  • People who wish to become pregnant (will not qualify for pregnancy prevention counseling)
  • Have a scheduled visit with a member of the investigative team (to minimize risk of potential ascertainment bias)
  • Participants of Aim 1 cannot participate in Aim 2.

Sexual and Reproductive Health clinicians will be included if they provide sexual and reproductive health patient care at any of the participating sites. Clinic staff will be included if they work at any of the participating sites and have patient-facing or non-patient-facing roles .

Treatment and study plan

PrEP Decision Aid

Device

Patient-facing decision-aid on PrEP that will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of counseling.

Generic Information

Other

Participants will be asked to watch a CDC-produced video, "PrEP (Pre-Exposure Prophylaxis" (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid.

Primary outcomes

  1. PrEP initiation (prescribing)

    Time frame: 6 months

    Whether PrEP was prescribed (yes/no) in the EHR within the 6-month time frame

  2. Feasibility of implementing the enhanced PrEP decision aid in SRH settings, according to the Proctor taxonomy

    Time frame: 6 months

    Feasibility is defined as the extent to which the enhanced PrEP decision aid can be successfully used in SRH clinic settings (qualitative).

  3. Acceptability of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)

    Time frame: 6 months

    Acceptability is defined as the user perception that the enhanced PrEP decision aid is acceptable in SRH settings.

  4. Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)

    Time frame: 6 months

    Penetration (reach) of the intervention, measured by recruitment rate (number of participants enrolled per month)

  5. Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)

    Time frame: 6 months

    Penetration (reach) of the intervention, measured by completion rate (percentage of participants completing 6-month interviews out of those enrolled)

  6. Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)

    Time frame: 6 months

    Penetration (reach) of the intervention, measured by reasons for not meeting inclusion criteria

  7. Adoption of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)

    Time frame: 6 months

    Adoption of the enhanced decision aid into SRH clinics, assessed by whether PrEP was discussed during the visit (yes/no)

Secondary outcomes

  1. PrEP initiation (dispensing)

    Time frame: 6 months

    Whether PrEP was dispensed (yes/no) in the EHR within the 6-month time frame

  2. PrEP initiation (first use)

    Time frame: 6 months

    Whether PrEP was started by the patient within the 6 months' time frame (yes/no)

  3. PrEP adherence

    Time frame: 6 months

    Non-pharmacokinetic: (subjective) 3-item self-report with 30-day look-back

  4. PrEP adherence

    Time frame: 6 months

    Non-pharmacokinetic: (objective) pharmacy refill data or injection dates for LAI.

  5. PrEP adherence

    Time frame: 6 months

    Pharmacokinetic: (objective) urine tenofovir levels (units detected/ not detected)

  6. PrEP persistence

    Time frame: 6 months

    Dates of completed PrEP encounters in EHR (i.e., clinic dates)

Study contacts

Contact information is provided by the study sponsor or research team.

Carolina Price, MPA

CONTACT

[email protected]

2034998075

Jaimie P Meyer, MD

CONTACT

[email protected]

2037376233

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

Project Carmenta: Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 12, 2024
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.